Circulating adiponectin levels and risk of type 2 diabetes in the Japanese

Nutrition and Diabetes

Volumn 4, Issue AUG, 2014, Pages

  Yamamoto, S ^a   Matsushita, Y ^b   Nakagawa, T ^a   Hayashi, T ^a   Noda, M ^b   Mizoue, T ^b  

^a HITACHI LTD   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRINKING BEHAVIOR; FAMILY HISTORY; FAT MASS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE; WAIST CIRCUMFERENCE;

EID: 84906849978     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.27     Document Type: Article

References (29)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorec CJ et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care 2013; 36: 1033-1046.
4. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
5. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
6. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14: 561-566.
7. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2009; 302: 179-188.
8. Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
9. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: The Funagata study. Diabetes Care 2003; 26: 2015-2020.
10. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 1745-1751.
11. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM et al. Adiponectin and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2004; 53: 2473-2478.
12. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 2006; 91: 3873-3877.
13. Snijder MB, Heine RJ, Seidell JC, Bouter LM, Stehouwer CD, Nijpels G et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: The Hoorn study. Diabetes Care 2006; 29: 2498-2503.
14. Tabák AG, Brunner EJ, Miller MA, Karanam S, McTernan PG, Cappuccio FP et al. Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 2009; 41: 626-629.
15. Zhu N, Pankow JS, Ballantyne CM, Couper D, Hoogeveen RC, Pereira M et al. High-molecular-weight adiponectin and the risk of type 2 diabetes in the ARIC study. J Clin Endocrinol Metab 2010; 95: 5097-5104.
16. Marques-Vidal P, Schmid R, Bochud M, Bastardot F, von Känel R, Paccaud F et al. Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study. PLoS One 2012; 7: e51768.
17. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007; 30: 1200-1205.
18. Hivert MF, Sullivan LM, Shrader P, Fox CS, Nathan DM, D'Agostino RB Sr et al. Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: The Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study. Diabetologia 2011; 54: 1019-1024.
19. Hanley AJ, Wagenknecht LE, Norris JM, Bergman R, Anderson A, Chen YI et al. Adiponectin and the incidence of type 2 diabetes in Hispanics and African Americans: The IRAS Family Study. Diabetes Care 2011; 34: 2231-2236.
20. Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008; 149: 307-316.
21. Matsushita Y, Nakagawa T, Yamamoto S, Kato T, Ouchi T, Kikuchi N et al. Adiponectin and visceral fat associate with cardiovascular risk factors. Obesity (Silver Spring, MD) 2014; 22: 287-291.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35 (Suppl. 1): S64-S71.
23. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
24. Heianza Y, Arase Y, Fujihara K, Tsuji H, Saito K, Hsieh SD et al. Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA(1c) and impaired fasting glucose: The Toranomon Hospital Health Management Center Study 4 (TOPICS 4). Diabet Med 2012; 29: e279-e285.
25. Nakamura Y, Sekikawa A, Kadowaki T, Kadota A, Kadowaki S, Maegawa H et al. Visceral and subcutaneous adiposity and adiponectin in middle-aged Japanese men: The ERA JUMP study. Obesity (Silver Spring, MD) 2009; 17: 1269-1273.
26. Torréns JI, Skurnick J, Davidow AL, Korenman SG, Santoro N, Soto-Greene M et al. Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: The Study of Women's Health Across the Nation (SWAN). Diabetes Care 2004; 27: 354-361.
27. Pham NM, Nanri A, Yasuda K, Kurotani K, Kuwahara K, Akter S et al. Habitual consumption of coffee and green tea in relation to serum adipokines: A cross-sectional study. Eur J Nutr 2014; e-pub ahead of print 22 April 2014; doi:10.1007/s00394-014-0701-4.
28. Wu JH1, Cahill LE, Mozaffarian D. Effect of fish oil on circulating adiponectin: A systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2013; 98: 2451-2459.
29. Esposito K, Giugliano D. Lifestyle and adiponectin level: four-year follow-up of controlled trials. Arch Intern Med 2010; 170: 1270-1271.